businesswire.com · 30 jun

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibito.

businesswire.com · 12 jun

BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton's tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic.

businesswire.com · 11 jun

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibr.

seekingalpha.com · 8 jun

BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

zacks.com · 5 jun

BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?

BeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

seekingalpha.com · 2 jun

BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript

BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript

marketbeat.com · 2 jun

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

BeOne Medicines NASDAQ: ONC used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company said are moving toward registrational development.

reuters.com · 1 jun

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Summit Therapeutics' shares rose as much as 7% before the bell after its ivonescimab therapy with China-based partner Akeso helped advanced lung cancer patients ​live 15% longer than BeOne Medicines' Tevimbra immunotherapy.